The researchers will evaluate the effectiveness of a complex intervention composed of multiple actions targeting primary care healthcare workers and postmenopausal women with osteoporosis by means of a quasi-experimental design in the form of a cluster-controlled trial with clustering at family physician level. The study has 2 study arms. In one arm, osteoporosis stakeholders receive a complex intervention (Integrated Osteoporosis Care(IOC)). The second study arm serves as control and receives care as usual. The complex intervention is composed of * education and provision of educational material for all stakeholders in primary osteoporosis care (patients, family physicians, nurse-educators, physiotherapists, dietitians, pharmacists and if present patient's informal caregivers) * patient self-management support by primary care osteoporosis stakeholders * the construction of a primary care osteoporosis treatment guideline and care pathway Effectiveness will be measured by questionnaires and data from the (Electronic Medical Record)EMR and IMA-database, in patients and family physicians. Effects measured in family physicians are: * Identification failure rate * Percentage of family physicians correctly implementing the osteoporosis treatment guideline * Proportion of patients treated correctly as stated in the osteoporosis treatment guideline * Proportion of family physicians correctly registering osteoporosis related information in the EMR * Intensity of collaborative practices * Knowledge of osteoporosis management and treatment Effects measured in patients are: * Medication Possession Ratio(MPR) (Primary outcome) * Health literacy * Self-management efficacy * Self-reported treatment adherence * Self-reported nutritional intake * Intensity of integrated osteoporosis care * Patient satisfaction with integrated osteoporosis care * HRQoL * Functional independence (Activities of Daily Living - ADL) * Patient resource use The study elapse time is 18 months. Participating family physicians will receive postgraduate education and start to include patients during consultations in their doctor's office. The inclusion period is 6 months, patients eligible for participation are non-institutionalized postmenopausal women with a diagnosis of osteoporosis who are able to give informed consent. The follow-up period for patients is 12 months. Follow-up period for family physicians is 18 months.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Medication Possession Ratio (MPR)
Timeframe: 12 months